Merck Pays $830M To End Investor Suit Over Vioxx Marketing
Merck announced Friday that it will pay $830 million to settle investors' claims in multidistrict litigation accusing the company of committing securities fraud violations by illegally marketing the painkiller Vioxx, after...To view the full article, register now.
Already a subscriber? Click here to view full article